For example, in clinical trials of semaglutide 2.4 mg (Wegovy), nausea occurred in approximately 44% of patients, while rates for tirzepatide and other GLP-1s vary: Nausea : Often described as mild queasiness, particularly after eating, though some patients experience more pronounced nausea Bloating and abdominal fullness : A sensation of delayed digestion or food sitting heavily in the stomach Changes in bowel habits : Constipation affects approximately 15-30% of patients (varying by medication and dose), while some experience diarrhea or alternating patterns [1] [4] Decreased appetite : Beyond simple fullness, many report a fundamental shift in food thoughts, with reduced cravings and less mental preoccupation with eating Some patients report fatigue or low energy , particularly during the initial weeks
This formulation combines Tirzepatidetargeting GLP-1 and GIP receptors to help regulate appetite, digestion, and blood sugarwith glycine, which supports muscle health
Results are expressed as median (IQR)
GLP-1 agonists work by Triggering insulin release from the pancreas Blocking glucagon secretion Slowing stomach emptying Increasing feelings of fullness Semaglutide helps lower blood sugar levels, reduce appetite, and promote weight loss by mimicking these effects
